Timely alterations of cardiovascular avoidable risk factors can be made if Lp-PLA2 levels are monitored in parallel with micronutrient supplementation to detect deficiencies at an early stage, along with general prevention strategies in treating patients with MetS. The gene discussed is PLA2G7; the disease is metabolic syndrome.